TABLE 1.
Baseline characteristics from two hospitals.
| Parameter | Hospital 1 | Hospital 2 |
|---|---|---|
| Number of patients (N) | 684 | 530 |
| Age | Median: 55; Range: (18–88) | Median: 60; Range: (18–88) |
| Gender | Female: 478 (70%) | Female: 337 (64%) |
| Male: 206 (30%) | Male: 193 (36%) | |
| Tumour type | Breast: 268 (39%) | Breast: 212 (40%) |
| DLBCL: 182 (27%) | DLBCL: 67 (13%) | |
| Colorectal: 234 (34%) | Colorectal: 251 (47%) | |
| Regimen received | FEC: 79 (12%) | FEC: 141 (27%) |
| T‐FEC: 189 (28%) | T‐FEC: 71 (13%) | |
| RCHOP: 182 (27%) | RCHOP: 67 (13%) | |
| FOLFOXIRI: 1 (0.1%) | FOLFOXIRI: 0 (0%) | |
| IRMDG: 26 (3.5%) | IRMDG: 67 (13%) | |
| OXCAP: 25 (3.4%) | OXCAP: 72 (13%) | |
| FOLFOX: 175 (26%) | FOLFOX: 112 (21%) | |
| Mean creatinine | 65.36 | 69.96 |
| Mean bilirubin | 6.90 | 6.64 |
| Patients with any deterioration at cycle 3 (creatinine) | 27 (4%) | 11 (2%) |
| Patients with any deterioration at cycle 3 (bilirubin) | 77 (11%) | 69 (13%) |
Abbreviations: DLBCL, diffuse large B‐cell lymphoma; EC, epirubicin and cyclophosphamide; FEC, fluorouracil, epirubicin and cyclophosphamide; Folfoxiri, fluorouracil, irinotecan, oxaliplatin; FOLFOX, Oxaliplatin modified de gramont; IRMDG, irinotecan modified de gramont; R‐CHOP, rituximab, cyclophosphamide, doxorubicin and prednisolone.